Kelli Luginbuhl, PhD
General Manager
-
Kelli received her PhD in Biomedical Engineering from Duke University where she studied the design and development of phase separating proteins for various biomedical applications. She co-founded Isolere Bio in 2018 with the mission of reimagining the way the industry approaches advanced therapeutics manufacturing.
Initially serving as Chief Scientific Officer, Kelli is an inventor on many of Isolere’s core patents. She transitioned into the CEO role in 2019 and helped secure a $7M seed round in 2021. She continues to lead the Isolere team in the role of General Manager, reporting to the President of Life Sciences after the acquisition and integration into Donaldson Company in 2023. The company is focused on the launch, scale up, and commercialization of first of its kind purification reagents for AAV, LV, and ssRNA.
Achieving high LV yields and purity with our chromatography-free process
Associate Director of R&D for Isolere Bio, Nikki Votaw, PhD, on innovative approaches to lentiviral vector purification, achieving high yields, and purity with a chromatography-free process. View Webinar→
Breaking free from Chromatography:
Transformative AAV Purification
Director of Advanced R&D, Michael Dzuricky, Ph.D., on how IsoTag™ AAV Reagent can achieve >90% AAV capture and 60-85% elution recoveries with our baseline protocol on the first run. View Webinar→